Latest press releases
- AstraZeneca Issues Update on Accelerated Oncology Pipeline in Advance of 2013 ASCO Annual Meeting
- 16 May 2013
- Taskforce meets to begin planning for future of Alderley Park
- 29 April 2013
- AstraZeneca PLC first quarter results 2013
- 25 April 2013
- AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine
- 22 April 2013
- AstraZeneca announces top-line results from OSKIRA-1 Phase III study of fostamatinib in rheumatoid arthritis
- 5 April 2013
- MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma
- 3 April 2013
- US District Court rules one PULMICORT RESPULES® (Budesonide Inhalation Suspension) patent invalid and another patent not infringed
- 2 April 2013
- AstraZeneca settles litigation over CRESTOR patent
- 25 March 2013
- AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy
- 21 March 2013
Photo library
AstraZeneca tweets
-
MT @pharmtechadels: AZ/Exco InTouch develop interactive mobile/internet-based health tools for disease management http://t.co/joCijE9es9
17 May -
Watch some of our highlights from this year’s visit to the @BIOConvention #LabTalk #BIO2013 http://t.co/8clbc3xUMc
14 May -
RT @EIO_org_uk: Congratulations @AstraZeneca 3rd in UK #EIO #CO2Rankings http://t.co/CgGJeZEbbA Report: http://t.co/GD6Yr0VUzY #greenbusine…
1 May
Fast facts
AstraZeneca is a global, innovation-driven biopharmaceutical business. We focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease.
Our innovative medicines are used by millions of patients worldwide.